Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer

• Hlavní autoři: Apoorva Daram (Autor), Shruti S. Sawant (Autor), Dhwani A. Mehta (Autor), Carlos A. Sanhueza (Autor), Nitesh K. Kunda (Autor)
• Médium: Kniha
• Vydáno: MDPI AG, 2024-11-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

<b>Background</b>: Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths globally. The most extensive treatment is Tyrosine Kinase Inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) overexpression. Osimertinib, a third-generation TKI is approved to tar...